Back to screener
Zim Laboratories Limited
₹135.51
▼ 2.41 (-1.75%) today
Latest quote · Yahoo Finance
Market Cap
₹726 Cr
P/E (TTM)
163.3
P/B
2.4
Book Value
₹55.35
ROE
1.2%
Div Yield
—
D/E
0.43
EPS (TTM)
₹0.83
52W High
₹144.49
52W Low
₹59.31
Sales Growth
+31.20%
Profit Growth
—
Day High
₹139.79
Day Low
₹130.20
Volume
1,27,424
Fundamentals refreshed 14 hr ago · Statements just now · Source: Yahoo Finance
Quick Take
- • Trading at 163.3× trailing earnings
- • Moderate ROE at 1.2%
- • Low leverage (D/E 0.43)
- • No dividend data
- • Operating margin -3.1% · Net margin 0.9%
- • Profit growth — YoY · Beta 0.83
Employees: 632
Latest quarter · Jun 2026
| ₹ Cr | Jun 2026 | QoQ | YoY |
|---|---|---|---|
| Revenue | 94 | -10.48% | +30.56% |
| Operating Profit | 3 | -76.92% | -50.00% |
| Net Profit | -4 | -200.00% | -100.00% |
| EPS (₹) | -0.75 | -198.68% | -97.37% |
OPM 3.7% · Net margin -4.3% · prev quarter OPM 12.7%
Shareholding Pattern
Numbers in percentages · Source: NSE
| Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters▲0.01 | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 30.30% | 30.35% | 30.36% |
| FIIs▲0.03 | 0.21% | 0.01% | 0.03% | 0.00% | 0.02% | 0.00% | 0.00% | 0.03% |
| DIIs▲1.26 | 0.24% | 0.24% | 0.24% | 0.24% | 0.20% | 0.07% | 0.07% | 1.33% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public▼1.30 | 66.28% | 66.49% | 66.46% | 66.51% | 66.52% | 69.63% | 69.58% | 68.28% |
| No. of Shareholders | 17,450 | 17,448 | 16,641 | 17,282 | 17,251 | 16,762 | 16,636 | 14,510 |
* N
Who is buying / selling · last 12 months (NSE)
| Date | Party | Type | Side | Qty | Price |
|---|---|---|---|---|---|
| 11 Nov 25 | Elimath Advisors Private Limited | Bulk deal | BUY | 38,40,000 | ₹73.47 |
| 11 Nov 25 | Elizabeth Mathew | Bulk deal | SELL | 38,40,000 | ₹73.45 |
| 29 Oct 25 | Ajit Ramkaran Sarda | Bulk deal | BUY | 2,65,483 | ₹81.58 |
| 29 Oct 25 | Ajit Ramkaran Sarda | Bulk deal | SELL | 1,42,892 | ₹82.02 |
| 24 Oct 25 | Elimath Advisors Private Limited | Bulk deal | BUY | 14,97,124 | ₹68.79 |
| 24 Oct 25 | Mathew Cyriac | Bulk deal | SELL | 15,69,000 | ₹68.84 |
About the company
From latest AR & concall Reading the latest annual report and earnings call… (1–3 min on first visit)
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was founded in 1984 and is based in Nagpur, India.
